TY - JOUR
T1 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1
T2 - Acute treatment of schizophrenia
AU - Falkai, Peter
AU - Wobrock, Thomas
AU - Lieberman, Jeffrey
AU - Glenthoj, Birte
AU - Gattaz, Wagner F.
AU - Möller, Hans Jürgen
AU - Altamura, A. Carlo
AU - Andreasen, Nancy
AU - Barnes, Thomas R.E.
AU - Beckmann, Helmut
AU - Ciprian-Ollivier, Jorge
AU - Crow, Tim
AU - David, Anthony
AU - Davidson, Michael
AU - Deakin, Bill
AU - Elkis, Helio
AU - Farde, Lars
AU - Gaebel, Wolfgang
AU - Gallhofer, Bernd
AU - Gerlach, Jes
AU - Hirsch, Steven Richard
AU - Hojaij, Carlos R.
AU - Jablensky, Assen
AU - Kane, John
AU - Kojima, Takuja
AU - von Knorring, Lars
AU - McGorry, Patrick
AU - Meltzer, Herbert
AU - Moussaoui, Driss
AU - Müller-Spahn, Franz
AU - Olie, Jean Pierre
AU - Palha, A. Pacheco
AU - Sato, Mitsumoto
AU - Sauer, Heinrich
AU - Schooler, Nina
AU - Weinberger, Daniel
AU - Yamawaki, Shigeto
PY - 2005/8
Y1 - 2005/8
N2 - These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.
AB - These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.
KW - Acute phase treatment
KW - Antipsychotics
KW - Biological treatment
KW - Evidence-based medicine
KW - Practice guidelines
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=33644698983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644698983&partnerID=8YFLogxK
U2 - 10.1080/15622970510030090
DO - 10.1080/15622970510030090
M3 - Review article
C2 - 16173147
AN - SCOPUS:33644698983
SN - 1562-2975
VL - 6
SP - 132
EP - 191
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 3
ER -